Preview

Rational Pharmacotherapy in Cardiology

Advanced search

CLINICAL PRACTICE OF BETA-BLOCKERS USAGE IN PATIENTS WITH CARDIOVASCULAR AND CHRONIC RESPIRATORY DISEASES. DATA OF OUTPATIENT REGISTRIES PROFILE AND RECVASA

https://doi.org/10.20996/1819-6446-2017-13-4-469-475

Full Text:

Abstract

Aim. To assess the practice of using beta-adrenoblockers (β-AB) in patients with cardiovascular diseases (CVD) in the presence of limitations (chronic obstructive pulmonary disease – COPD) and contraindications (bronchial asthma – BA) in two outpatient registries PROFILE and RECVASA.

Material and methods. The data of the PROFILE registry organized in the specialized cardiological unit of the medical research center in Moscow from 2011 to 2015 (n=1531) were analyzed as well as data of the RECVASA registry included patients who applied to 3 city outpatient clinics in Ryazan from 2012 to 2013 (n=3690).

Results. In the RECVASA registry 279 patients had COPD (mean age 73 years; 59.4% males); in the PROFILE registry 286 patients had COPD (mean age 66 years; 50.2% males). In the presence of COPD in the PROFILE registry, β-AB were prescribed more often (51.1%) than in the RECVASA registry (31.5%, p<0.01), primarily to patients with high cardiovascular risk [after myocardial infarction (MI) and in patients with chronic heart failure (CHF)]. In the PROFILE registry 28 patients had BA (mean age 67 years; 46.4% males); in the RECVASA registry – 188 patients (mean age 64 years; 16.5% males). In patients with BA the frequency of β-AB prescription decreased in both registries: 28.6% in the PROFILE registry and 19.1% in the RECVASA registry (p<0.01). In the PROFILE registry the presence of COPD did not influence β-AB administration is patients with ischemic heart disease and MI history; in the RECVASA registry in the presence of COPD the probability of β-AB administration decreased in patients with ischemic heart disease, MI and CHF. In the presence of BA the probability of β-AB administration decreased in both registries in all patients except hypertensive ones.

Conclusion. Physicians of a specialized institution are more active than physicians of outpatient clinics in prescribing β-AB in COPD when direct indications to β-AB are present (previous MI, CHF) except uncomplicated hypertension. In patients with CVD and BA, doctors in both registries try not to prescribe β-AB. However, in uncomplicated hypertension, BA was often not taken into account, while prescribing β-AB. 

About the Authors

S. Yu. Martsevich
National Medical Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


N. A. Zakharova
National Medical Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


N. P. Kutishenko
National Medical Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


A. V. Zagrebelnyy
National Medical Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


Yu. V. Lukina
National Medical Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


M. M. Loukianov
National Medical Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


A. N. Vorobyev
I.P. Pavlov Ryazan State Medical University
Russian Federation
Visokovoltnaya ul. 9, Ryazan, 390026


A. N. Kozminsky
I.P. Pavlov Ryazan State Medical University
Russian Federation
Visokovoltnaya ul. 9, Ryazan, 390026


References

1. Steg P.G., James S.K., Atar D., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-619.

2. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2013;128(16):e137-61.

3. Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34(38):2949-3003.

4. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28): 2159-219.

5. Uk J.M., UkH.D., Poland M.T., et al. Expert consensus document on β-adrenergic receptor blockersThe Task Force on Beta-Blockers ofthe European Society of Cardiology. EurHeartJ. 2004;25(15):1341-62.

6. Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-St-ElevationAcute Coronary Syndromes.JAm Coll Cardiol. 2014;64(24):e139-228.

7. Opie L.H., Gersh B.J. Drug for the heart 8th edition. Philadelphia: Elsevier Saunders; 2013.

8. Boytsov S.A., Chuchalin A.G. Prevention of chronic non-infectious diseases. Guidelines. 2013. Available at: https://www.gnicpm.ru/UserFiles/Profilaktika_khronicheskikh_neinfekcionnykh_zabolevanijj.pdf. Checked by 08/17/2012. (In Russ.) [Бойцов С.А., Чучалин А.Г. Профилактика хронических неинфекционных заболеваний. Рекомендации. 2013. Доступно на: https://www.gnicpm.ru/UserFiles/Profilaktika_khronicheskikh_neinfekcionnykh_zabolevanijj.pdf. Проверено 17.08.2017].

9. Halbert R.J., Natoli J.L., Gano A., et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523-32.

10. MenezesA.M.B., Perez-Padilla R.,Jardim J.R.B., et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): A prevalence study. Lancet. 2005;366(9500):1875-81.

11. The top 10 causes of death. Fact sheet, Updated January 2017. Geneva: World Health Organization; 2017.

12. Martsevich S.Yu., Navasardyan A.R., Kutishenko N.P., etc. Experience of studying atrial fibrillation on the basis of the register PROFILE. Kardiovaskulyarnaya Terapiya i Profilaktika. 2014;13 (2):35-9. (In Russ.) [Марцевич С.Ю.,НавасардянА.Р., КутишенкоН.П., и др. Опыт изучения фибрилляции предсердий на базе регистра ПРОФИЛЬ. Кардиоваскулярная Терапия и Профилактика. 2014;13(2):35-9].

13. Martsevich S.Yu., Navasardyan A.R., Kutishenko N.P., Zakharova A.V. Assessment of adherence to the use of new oral anticoagulants in patients with atrial fibrillation according to the PROFILE registry. Rational Pharmacotherapy in Cardiology. 2014;10(6):625-30. (In Russ.) [Марцевич С.Ю., Навасардян А.Р., Кутишенко Н.П., Захарова А.В. Оценка приверженности к приему новых пероральных антикоагулянтов у пациентов с фибрилляцией предсердий по данным регистраПРОФИЛЬ. Рациональная Фармакотерапия в Кардиологии. 2014;10(6):625-30].

14. Martsevich S.Yu., Navasardyan A.R., Kutishenko N.P., et al. Evaluation of the dynamics of prescribing antithrombotic agents in patients with atrial fibrillation according to the data of the PROFILE register. Kardiovaskulyarnaya Terapiya i Profilaktika.2015;14(1):35-40. (In Russ.) [Марцевич С.Ю., Навасардян А.Р., Кутишенко Н.П., и др. Оценка динамики назначения антитромботических препаратов у пациентов с фибрилляцией предсердий по данным регистра ПРОФИЛЬ. Кардиоваскулярная Терапия и Профилактика. 2015;14(1):35-40].

15. Lukina Yu.V.,Dmitrieva N.A., Zakharova A.V., et al. Undesirable effects of drug therapy (the firstresults of the study according to the PROFILE outpatient registry. Rational Pharmacotherapy in Cardiology. 2016;12(3):306-13. (In Russ.) [Лукина Ю.В.,Дмитриева Н.А., Захарова А.В., и др.Нежелательные явления лекарственной терапии (первые результаты исследования по данным амбулаторного регистра ПРОФИЛЬ. Рациональная Фармакотерапия в Кардиологии. 2016;12(3):306-13].

16. Zagrebelny A.V., Martsevich S.Yu., Loukyanov M.M., et al. Assessment of the quality of prescription of antihypertensive drugs for patientswith arterial hypertensionwho do not have a combined cardiovascular pathology within the RECVASA outpatientregistry. Rational Pharmacotherapy in Cardiology. 2014; 10 (4): 378-83. (In Russ.) [Загребельный А.В., Марцевич С.Ю., Лукьянов М.М., et al. Оценка качества назначения антигипертензивных препаратов больным артериальной гипертонией, не имеющих сочетанной сердечно-сосудистой патологии, в рамках амбулаторно-поликлинического регистра РЕКВАЗА. Рациональная Фармакотерапия в Кардиологии. 2014;10(4):378-83].

17. Boytsov S.A., Loukyanov M.M., Yakushin S.S., et al. Registry of cardiovascular diseases (RECVASA): diagnostics, combined cardiovascular pathology, concomitant diseases and treatment in conditions of real outpatient and polyclinic practice. Kardiovaskulyarnaya Terapiya i Profilaktika. 2014;13(6):44-50. (In Russ.) [Бойцов С.А., Лукьянов М.М., Якушин C.С., и др. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. Кардиоваскулярная Терапия и Профилактика. 2014;13(6):44-50].

18. Boitsov S.A., Loukyanov M.M., Yakushin S.S., et al. RECVASA outpatient registкн: data from prospectiveobservation,risk assessment andoutcomes in patients with cardiovascular diseases. Kardiovaskulyarnaya Terapiya i Profilaktika. 2015;14(1):53-62. (In Russ.) [Бойцов С.А., Лукьянов М.М., Якушин C.С., и др. Амбулаторно-поликлинический регистр РЕКВАЗА: данные проспективного наблюдения , оценка риска и исходы у больных с кардиоваскулярными заболеваниями. Кардиоваскулярная Терапия и Профилактика. 2015;14(1):53-62].

19. Martsevich S.Y., Kutishenko N.P., Tolpygina S.N., et al. Efficacy and safety of drug therapy in primary and secondary prevention of cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2011;7(5):2-72. (In Russ.) [Марцевич С.Ю., Кутишенко Н.П., Толпыгина С.Н., и др. Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Рациональная Фармакотерапия в Кардиологии. 2011;7(5):2-72].

20. Martsevich S.Yu., Zakharova N.A., Kutishenko N.P., et al. Study ofthe practice of prescribing beta-blockers and its correspondence to modern clinical recommendations within the framework of two outpatient registers of cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2016;12(3):260-4 (In Russ.) [Марцевич С.Ю., Захарова Н.А., Кутишенко Н.П., и др. Изучение практики назначения бета-адреноблокаторов и ее соответсвия современным клиническим рекомендациям в рамках двух амбулаторных регистров сердечно-сосудистых заболеваний. Рациональная Фармакотерапия в Кардиологии. 2016;12(3):260-4].

21. Martsevich S.Yu., Lukina Yu.V., Zagrebelny A.V., et al. Combined antihypertensive therapy in real clinical practice. Focus on fixed combinations of antihypertensive drugs (according to the data of RECVASA and PROFILE outpatient registries). Rational Pharmacotherapy in Cardiology. 2017;13(3):323-9 (In Russ.) [Марцевич С.Ю., Лукина Ю.В., Загребельный А.В., и др. Комбинированная антигипертензивная терапия в реальной клинической практике. Фокус на фиксированные комбинации антигипертензивных препаратов (по данным амбулаторных регистров РЕКВАЗАиПРОФИЛЬ). Рациональная Фармакотерапия в Кардиологии. 2017;13(3):323-9].

22. Quint J.K., Herrett E., Bhaskaran K., et al. Effect of beta blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650.

23. Lipworth B., SkinnerD.,Devereux G., et al. Underuse of β-blockers in heartfailure and chronic obstructive pulmonary disease. Heart. 2016;102(23):1909-14.

24. Tendera M., Fox K., Ferrari R., et al. Inadequate heartrate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. Int J Cardiol. 2014;176(1):119-24.

25. Order 520n from 15.07.2016 of the Ministry of Health of the Russian Federation. On the approval of criteria for assessing the quality of care. 2016. Available at: https://minjust.consultant.ru/documents/20356?items=1&page=1. Checked by 08/17/2012. (In Russ.) [Приказ 520н от 15.07.2016 МЗ РФ. Об утверждении критериев оценки качества медицинской помощи. 2016.Доступно на: https://minjust.consultant.ru/documents/20356?items=1&page=1. Проверено 17.08.2017].

26. Federal Law "On the circulation of medicines" of 12.04.2010 №61-FZ. Available at: www.consultant.ru/document/cons_doc_LAW_99350/. Checked by 08/17/2012. (In Russ.) [Федеральный закон “Об обращении лекарственных средств” от 12.04.2010№61-ФЗ. Доступно на: www.consultant.ru/document/cons_doc_LAW_99350/. Проверено 17.08.2017].


For citation:


Martsevich S.Y., Zakharova N.A., Kutishenko N.P., Zagrebelnyy A.V., Lukina Y.V., Loukianov M.M., Vorobyev A.N., Kozminsky A.N. CLINICAL PRACTICE OF BETA-BLOCKERS USAGE IN PATIENTS WITH CARDIOVASCULAR AND CHRONIC RESPIRATORY DISEASES. DATA OF OUTPATIENT REGISTRIES PROFILE AND RECVASA. Rational Pharmacotherapy in Cardiology. 2017;13(4):469-475. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-4-469-475

Views: 201


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)